Edition:
International

Pharmaceuticals

Biogen Announces Topline Results From Phase 2 Study Of Gosuranemab, An Anti-Tau Antibody, For Alzheimer’S Disease

June 16 (Reuters) - Biogen Inc ::BIOGEN ANNOUNCES TOPLINE RESULTS FROM PHASE 2 STUDY OF GOSURANEMAB, AN ANTI-TAU ANTIBODY, FOR ALZHEIMER’S DISEASE.BIOGEN INC - GOSURANEMAB DID NOT MEET ITS PRIMARY EFFICACY ENDPOINT OF CHANGE FROM BASELINE AT WEEK 78 ON CLINICAL DEMENTIA RATING SCALE-SUM OF...

4:30pm EDT

U.S. CDC Says 146,456,124 Individuals Have Been Fully Vaccinated Against Covid-19 As Of June 16

June 16 (Reuters) - U.S. CDC::U.S. CDC SAYS 146,456,124 INDIVIDUALS HAVE BEEN FULLY VACCINATED AGAINST COVID-19 AS OF JUNE 16 VERSUS 145,768,367 INDIVIDUALS AS OF JUNE 15.U.S. CDC SAYS DELIVERED 375,186,675 DOSES OF COVID-19 VACCINE AS OF JUNE 16 VERSUS 374,865,165 DOSES DELIVERED AS OF JUNE 15.U.S....

2:07pm EDT

U.S. CDC Says 146,456,124 Individuals Have Been Fully Vaccinated Against Covid-19 As Of June 16

June 16 (Reuters) - U.S. CDC::U.S. CDC SAYS 146,456,124 INDIVIDUALS HAVE BEEN FULLY VACCINATED AGAINST COVID-19 AS OF JUNE 16 VERSUS 145,768,367 INDIVIDUALS AS OF JUNE 15.U.S. CDC SAYS DELIVERED 375,186,675 DOSES OF COVID-19 VACCINE AS OF JUNE 16 VERSUS 374,865,165 DOSES DELIVERED AS OF JUNE 15.U.S....

2:07pm EDT

Elanco Announces Agreement To Buy Kindred Biosciences

June 16 (Reuters) - Elanco Animal Health Inc ::ELANCO ANNOUNCES AGREEMENT TO ACQUIRE KINDRED BIOSCIENCES.WILL ACQUIRE ALL OUTSTANDING STOCK OF KINDRED BIOSCIENCES AT A PRICE OF $9.25 PER SHARE, OR APPROXIMATELY $440 MILLION.ELANCO ANIMAL HEALTH - DEAL AND OPERATING COSTS SLIGHTLY DILUTIVE TO CO'S...

6:30am EDT

Expansion & New Markets

Markets

  • Sectors
  • U.S.
  • Europe
  • Asia

Sector Summary

Upcoming Events

No related earnings announcements are currently scheduled within the next 7 days.